Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to -$340.7 million.

  • Ptc Therapeutics' Net Cash Flow fell 14815.72% to -$340.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.2 million, marking a year-over-year decrease of 5981.3%. This contributed to the annual value of $192.4 million for FY2024, which is 3819.66% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Net Cash Flow stood at -$340.7 million, which was down 14815.72% from -$476.4 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Net Cash Flow registered a high of $695.2 million during Q1 2025, and its lowest value of -$476.4 million during Q2 2025.
  • Moreover, its 5-year median value for Net Cash Flow was -$19.4 million (2023), whereas its average is $24.8 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Net Cash Flow skyrocketed by 437185.85% in 2022, and later crashed by 53662.22% in 2025.
  • Ptc Therapeutics' Net Cash Flow (Quarter) stood at $3.8 million in 2021, then skyrocketed by 4371.86% to $169.4 million in 2022, then soared by 151.35% to $425.8 million in 2023, then plummeted by 37.95% to $264.2 million in 2024, then tumbled by 228.97% to -$340.7 million in 2025.
  • Its last three reported values are -$340.7 million in Q3 2025, -$476.4 million for Q2 2025, and $695.2 million during Q1 2025.